
Feb 19 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES OPDIVO® PLUS CHEMOTHERAPY AS THE FIRST AND ONLY NEOADJUVANT-ONLY IMMUNO-ONCOLOGY THERAPY TO DEMONSTRATE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL OVERALL SURVIVAL IN RESECTABLE NON-SMALL CELL LUNG CANCER
BRISTOL-MYERS SQUIBB CO - STUDY SHOWS SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL WITH OPDIVO PLUS CHEMOTHERAPY
BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY SIGNALS OBSERVED WITH OPDIVO PLUS CHEMOTHERAPY
Source text: ID:nBw3XKR9ga
Further company coverage: BMY.N